Merck Patent Association

The present invention relates to liquid-crystalline (LC) media or LC materials and to energy efficient liquid-crystal displays (LCDs) containing these media, especially to gaming displays and AR/VR headsets addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

The present invention relates to liquid-crystalline (LC) media or LC materials and to energy efficient liquid-crystal displays (LCDs) containing these media, especially to gaming displays and augmented reality (AR) / virtual reality (VR) headsets addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

The invention relates to ionizable cationic amino lipids and lipid-based delivery systems, such as lipid particles comprising ionizable cationic amino lipids of the invention and their use for delivering a payload into a cell.

The present invention relates to liquid-crystalline (LC) media or LC materials and to energy efficient liquid-crystal displays (LCDs) containing these media, especially to gaming displays and AR/VR headsets addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.

The disclosed and claimed subject matter relates to formulations that include (i) one or more alkynes in combination with (ii) one or more tertiary alcohols as well as their use for enhanced passivation of metallic substrates.

The present invention relates to a liquid crystal medium and liquid crystal material comprising a) one or more compounds of formula I and one or more compounds of the formula T:in which the occurring groups and parameters have the meanings defined in claim 1, and to an electronic component comprising said LC medium, operable in the visible (VIS), infrared (IR) or microwave region of the electromagnetic spectrum. The invention further relates to the use of said LC medium in the IR, VIS or microwave region and to devices comprising said electronic component.

The instant invention relates to an optical component and a electro optical devices comprising the optical component. The instant invention further relates to a cholesteric polymerizable liquid crystalline (LC) material preferably utilized in an optical component in accordance with the present invention, to a process for the production of the cholesteric polymerizable LC material, to a process to convert the cholesteric polymerizable material into a polymer film, a polymer film obtainable from the cholesteric polymerizable LC material, the use of the polymer films in an optical component or device comprising a polymer film in accordance with the invention.

The invention relates to coating solutions comprising a polyol, a polymer, and a solvent, wherein the polyol is mannitol or xylitol and the polymer is an aqueous soluble polymer or a cellulose based polymer, and the use of said coating solutions in the coating of medicaments. The invention further relates to a method for coating a medicament and the use of mannitol in a coating solution for medicaments.

The present invention relates to pharmaceutical compositions comprising a therapeutic peptide having a molecular weight between 1 kDa and 100 kDa dispersed in an inorganic mesoporous material, said inorganic mesoporous material being in particular mesoporous silica.

The invention relates to a pharmaceutical composition comprising an active pharmaceutical ingredient (API), a carrier polymer, and tryptophan; as well as to a pharmaceutical composition according to the invention for use as a medicament. The invention further relates to a method for producing a pharmaceutical composition comprising the steps of a) mixing an API and a carrier polymer, and b) adding tryptophan.